NewsDiseasesSymptomsInjuriesDrugsProceduresToolsSelf-care


Featured Video:
Richard Joseph Discusses Treatment Outcomes for Metastatic Melanoma
















  Subtypes


Related Drugs:

Web

  • Decarboxylase inhibitor - RightDiagnosis.com
  • http://www.rightdiagnosis.com/medical/decarboxylase_inhibitor.htm
  • Decarboxylase inhibitor information including symptoms, causes, diseases, symptoms, treatments, and other medical and health issues.
    		•
  • Pharmacologic treatment of Parkinson disease
  • http://www.uptodate.com/contents/pharmacologic-treatment-of-parki...
  • In the United States, the decarboxylase inhibitor is carbidopa.The combination drug carbidopa-levodopa (immediate-release Sinemet) is available in tablets of 10/100, 25/100, and 25/250 mg, with the numerator referring to carbidopa and the denominator...
    		•
  • International Review of Neurobiology via MedWorm.com ; Chapter Seven Endocannabinoid Signaling in Motivation, Reward, and Addiction
  • http://www.medworm.com/rss/medicalfeeds/source/International+Revi...
  • Publication date: 2014 Source:International Review of Neurobiology, Volume 119 Author(s): Tomoyuki Kanda , Shin-ichi Uchida Dopamine replacement therapy using the dopamine precursor, l-3,4-dihydroxyphenylalanine (l-DOPA), with a peripheral dopa decarboxy...
    		•
  • Levodopa for restless legs syndrome - National Library of Medicine
  • http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0013513/
  • Background: Levodopa plus dopamine decarboxylase inhibitor is a common treatment for restless legs syndrome (RLS).
    		•
  • Entacapone 200 mg Film-Coated Tablets - Summary of Product Characteristics (SPC)
  • http://www.medicines.org.uk/emc/medicine/27766
  • One 200 mg tablet is taken with each levodopa/dopa decarboxylase inhibitor dose.
    		•
  • Skin Cancer Prevention (PDQ
  • http://www.uwhealth.org/health/topic/nci/skin-cancer-prevention-p...
  • Alpha-difluoromethylornithine (DFMO), an ornithine decarboxylase inhibitor used in intravenous form to treat African trypanosomiasis and in topical form to treat female hirsutism, was investigated as a chemopreventive agent in patients with prior NMSCs.[...
    		•
  • Skin Cancer Prevention (PDQ(R)) - Siteman Cancer Center
  • https://siteman.wustl.edu/ncipdq/cdr0000062764/
  • Alpha-difluoromethylornithine (DFMO), an ornithine decarboxylase inhibitor used in intravenous form to treat African trypanosomiasis and in topical form to treat female hirsutism, was investigated as a chemopreventive agent in patients with prior NMSCs....
    		•
  • Parkinson's disease
  • http://www.netdoctor.co.uk/conditions/brain-and-nervous-system/a1...
  • Short-term side-effects are uncommon but include nausea, hallucinations, tiredness and light-headedness, which may be relieved by taking the medication with food or increasing the dose of the decarboxylase inhibitor.
    		•
  • Extracerebral decarboxylase inhibitor - Wikipedia, the free encyclopedia
  • https://en.wikipedia.org/wiki/Extracerebral_decarboxylase_inhibitor
  • Extracerebral decarboxylase inhibitor is an inhibitory enzyme.It is used to inhibit the decarboxylation of L-DOPA to Dopamine outside the brain, i.e. in the blood.
    		•
  • JAMA Network ; JAMA Neurology ; Long-term Follow-up of Taiwanese Chinese Patients Treated Early for 6-Pyruvoyl-Tetrahydropterin Synthase Deficiency
  • http://archneur.jamanetwork.com/article.aspx?articleid=795338&...
  • The initial dosage of levodopa with a decarboxylase inhibitor was 2 mg/kg/d, then increased every 2 to 5 days in 1-mg increments to a target dosage of 10 to 15 mg/kg/d.
    		•
    1 2 3 4 5 6 7 8 9 ⇨

    News

  • Histidine decarboxylase inhibitors: a novel therapeutic option for the treatment of leydigioma
    Endocrinology-journals - Thursday, October 6, 2022
    		•
  • Outcomes and characteristics of patients on protease inhibitors at a tertiary level antiretroviral clinic
    Sajhivmed - Saturday, February 24, 2024
    		•
  • SGLT2 Inhibitors Tied to Better NAFLD Outcomes vs Other Antidiabetic Agents
    Medpage Today - Saturday, February 24, 2024
    		•
  • INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
    Cancer Discovery - Saturday, February 24, 2024
    		•
  • Heparanase Inhibitors May Reduce Risk of Diabetic Kidney Disease, Diabetic Retinopathy in Patients with Diabetes
    News Now - Thursday, February 8, 2024
    		•
  • The impact of 2023 EMA recommendations on patients treated with JAK inhibitors: real-life experience from a prospective monocentric cohort
    Oxford Journals - Thursday, February 8, 2024
    		•
  • Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
    Aacr Journals - Monday, January 29, 2024
    		•
  • Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
    Jama Network - Monday, January 29, 2024
    		•
  • Multivariate Statistical 2D QSAR Analysis of Indenoisoquinoline-based Topoisomerase- I Inhibitors as Anti-lung Cancer Agents
    Ingentaconnect - Sunday, January 14, 2024
    		•
  • Long-term use of proton pump inhibitors found to carry increased risk of death
    Independent - Sunday, January 14, 2024
    		•
  • The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models [Letter]
    Dove Press - Monday, December 25, 2023
    		•
  • Skye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab
    EIN News - Monday, December 11, 2023
    		•
  • Osteoclast-Cancer Cell Metabolic Crosstalk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer
    Aacr Journals - Monday, December 11, 2023
    		•
  • Response to: Correspondence on "Beta-blockers and renin-angiotensin system inhibitors for Takotsubo syndrome recurrence: a network meta-analysis" by John E Madias
    Heart - Monday, November 13, 2023
    		•
  • Cumulative Use of Proton Pump Inhibitors and Risk of DementiaThe Atherosclerosis Risk in Communities Study
    Neurology - Tuesday, October 31, 2023
    		•
  • An oncolytic virus-delivered TGF? inhibitor overcomes the immunosuppressive tumor microenvironment
    Rupress - Saturday, August 19, 2023
    		•
  • 08:00 ET Erleada(R) (apalutamide) 240 mg Approved as the Only Androgen Receptor Inhibitor with a Once-daily Single-Tablet Option in Canada
    Newswire - Wednesday, August 9, 2023
    		•
  • CDK9 inhibitors: A promising new treatment for hematological malignancies
    News-Medical - Wednesday, August 9, 2023
    		•
    MORE NEWS

    Videos

    Proteasome inhibitors in myeloma
           
    Proteasome inhibitors are an important type of drug used to treat myeloma. This animation describes how proteasomes inhibitors work and why they are useful in myeloma.
    Endocrine Therapy, Tamoxifen & Aromatase Inhibitors
           
    Joanne Mortimer, MD, Director of the Womens Cancers Program at City of Hope Comprehensive Cancer Center, Duarte, California
    Novel Bcl-2 specific inhibitor results - impressive responses in high-risk CLL
           
    Visit http://ecancer.org/ for more. At a press conference at EHA 2014, Dr Seymour (Peter MacCallum Cancer Centre, Melbourne, Australia) presents the findings surrounding the use of an oral drug, ABT-199/GDC-0199 which was designed to exclusively mimic ...
    ACE Inhibitor Associated Angioedema
           
    This patient presents with angioedema most likely secondary to the lisinopril that she is taking for hypertension. The medication was stopped. No airway compromise noted. The angioedema was localized to the lower lip.
    Managing Side Effects of mTOR Inhibitors in Cancer
           
    Naomi Haas, of the Abramson Cancer Center, explains the potential side effects of a class of drugs called mTOR inhibitors, primarily the agents Sutent (sunitinib) and Nexavar (sorafenib). mTOR inhibitors target the blood vessels, but they also have othe...
    Checkpoint Inhibitors: Taking the Brakes Off the Immune System
           
    This video is part of the Cancer Research Institute’s series “Immunotherapy: 5 Ways to Stop Cancer.” For more information on treating cancer with immunotherapy, visit http://www.cancerresearch.org. Checkpoint inhibitors are a very promising avenue ...
    Alimentary canal and Action of enzymes
           
    Follow us at: https://plus.google.com/+tutorvista/ Check us out at http://www.tutorvista.com/content/science/science-ii/nutrition/alimentary-canal.php Tube through which food passes in animals it extends from the mouth to the anus and forms a lar...
    Mayo Clinic: New Model To Assess Breast Cancer Risk More Accurate Than Current Option
           
    Aromatase Inhibitors in Breast Cancer Survivors
    PARP Inhibitors & Women with Ovarian Cancer
           
    Prof. A. Hilary Calvert, Clinical Director of Northern Institute for Cancer Research received the 2010 ESMO Lifetime Award for Carboplatin Work. Here he discusses PARP inhibitors and their importance for women with ovarian cancer.
    Overcoming cancer resistance with enzyme inhibitors
           
    Visit http://www.ecancer.org for more. Prof Helleday (Karolinska Institutet, Stockholm, Sweden) talks to ecancertv at the 26th EORTC-NCI-AACR Symposium about a non-essential enzyme that repairs DNA damage done to cancer cells during anti-cancer treatme...
    1 2 3 4 5 6 7 8 9 ⇨

    Images

    Immune Checkpoint Inhibitor (CTLA-4)
    Immune Checkpoint Inhibitor (PD-1)
    An enzyme binding site that would normally bind substrate can alternatively bind a competitive inhibitor, preventing substrate access.
    fraction of the enzyme population bound by inhibitor
    the effect of the inhibitor is a result of the percent of the enzyme population interacting with inhibitor.
    Immune Checkpoint Inhibitor (CTLA-4)
    cancer.gov    		 Immune Checkpoint Inhibitor (PD-1)
    cancer.gov    		 An enzyme binding site that would normally bind substrate can alternatively bind a competitive inhibitor, preventing substrate access.
    en.wikipedia.org    		 fraction of the enzyme population bound by inhibitor
    en.wikipedia.org    		 the effect of the inhibitor is a result of the percent of the enzyme population interacting with inhibitor.
    en.wikipedia.org
    1xan: HUMAN GLUTATHIONE REDUCTASE IN COMPLEX WITH A XANTHENE INHIBITOR
    1bwc: STRUCTURE OF HUMAN GLUTATHIONE REDUCTASE COMPLEXED with AJOENE INHIBITOR AND SUBVERSIVE SUBSTRATE
    Captopril, the first synthetic ACE inhibitor
    Blister pack of Prozac (fluoxetine), a selective serotonin reuptake inhibitor
    (A) Magnified Active Site of Ornithine Decarboxylase with PLP-Eflornithine-Cys-360 intermediate complex (B) Important residues in ODC active site with intermediate state of Eflornithine (black) and PLP (red) complex[29] Derived from Grishin, Nick V., et a
    1xan: HUMAN GLUTATHIONE REDUCTASE IN COMPLEX WITH A XANTHENE INHIBITOR
    en.wikipedia.org    		 1bwc: STRUCTURE OF HUMAN GLUTATHIONE REDUCTASE COMPLEXED with AJOENE INHIBITOR AND SUBVERSIVE SUBSTRATE
    en.wikipedia.org    		 Captopril, the first synthetic ACE inhibitor
    en.wikipedia.org    		 Blister pack of Prozac (fluoxetine), a selective serotonin reuptake inhibitor
    en.wikipedia.org    		 (A) Magnified Active Site of Ornithine Decarboxylase with PLP-Eflornithine-Cys-360 intermediate complex (B) Important residues in ODC active site with intermediate state of Eflornithine (black) and PLP (red) complex[29] Derived from Grishin, Nick V., et a
    en.wikipedia.org
    1gag: CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR
    350px Simvastatin Structural Formulae
    β-alanine: an amino acid produced by aspartate 1-decarboxylase and a precursor to coenzyme A[7]
    2e1w: Crystal structure of adenosine deaminase complexed with potent inhibitors
    1wxz: Crystal structure of adenosine deaminase ligated with a potent inhibitor
    1gag: CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR
    en.wikipedia.org    		 350px Simvastatin Structural Formulae
    en.wikipedia.org    		 ?-alanine: an amino acid produced by aspartate 1-decarboxylase and a precursor to coenzyme A[7]
    en.wikipedia.org    		 2e1w: Crystal structure of adenosine deaminase complexed with potent inhibitors
    en.wikipedia.org    		 1wxz: Crystal structure of adenosine deaminase ligated with a potent inhibitor
    en.wikipedia.org
    1wxy: Crystal structure of adenosine deaminase ligated with a potent inhibitor
    1v7a: Crystal structures of adenosine deaminase complexed with potent inhibitors
    1v79: Crystal structures of adenosine deaminase complexed with potent inhibitors
    1uml: Crystal structure of adenosine deaminase complexed with a potent inhibitor FR233624
    1o5r: Crystal structure of adenosine deaminase complexed with a potent inhibitor
    1wxy: Crystal structure of adenosine deaminase ligated with a potent inhibitor
    en.wikipedia.org    		 1v7a: Crystal structures of adenosine deaminase complexed with potent inhibitors
    en.wikipedia.org    		 1v79: Crystal structures of adenosine deaminase complexed with potent inhibitors
    en.wikipedia.org    		 1uml: Crystal structure of adenosine deaminase complexed with a potent inhibitor FR233624
    en.wikipedia.org    		 1o5r: Crystal structure of adenosine deaminase complexed with a potent inhibitor
    en.wikipedia.org
    6pah: HUMAN PHENYLALANINE HYDROXYLASE CATALYTIC DOMAIN DIMER WITH BOUND L-DOPA (3,4-DIHYDROXYPHENYLALANINE) INHIBITOR
    5pah: HUMAN PHENYLALANINE HYDROXYLASE CATALYTIC DOMAIN DIMER WITH BOUND DOPAMINE INHIBITOR
    4pah: HUMAN PHENYLALANINE HYDROXYLASE CATALYTIC DOMAIN DIMER WITH BOUND NOR-ADRENALINE INHIBITOR
    3pah: HUMAN PHENYLALANINE HYDROXYLASE CATALYTIC DOMAIN DIMER WITH BOUND ADRENALINE INHIBITOR
    400px Glycine decarboxylase complex svg
    6pah: HUMAN PHENYLALANINE HYDROXYLASE CATALYTIC DOMAIN DIMER WITH BOUND L-DOPA (3,4-DIHYDROXYPHENYLALANINE) INHIBITOR
    en.wikipedia.org    		 5pah: HUMAN PHENYLALANINE HYDROXYLASE CATALYTIC DOMAIN DIMER WITH BOUND DOPAMINE INHIBITOR
    en.wikipedia.org    		 4pah: HUMAN PHENYLALANINE HYDROXYLASE CATALYTIC DOMAIN DIMER WITH BOUND NOR-ADRENALINE INHIBITOR
    en.wikipedia.org    		 3pah: HUMAN PHENYLALANINE HYDROXYLASE CATALYTIC DOMAIN DIMER WITH BOUND ADRENALINE INHIBITOR
    en.wikipedia.org    		 400px Glycine decarboxylase complex svg
    en.wikipedia.org

    About Seenso | Mission Statement | Disclosure | Privacy | Policy Disclaimers | Terms and Conditions | Contact Us | | |